Yogev Debbi is the Co-founder and CEO of Mana.bio, an AI-driven drug delivery company leveraging machine learning and high-throughput screening to develop tissue-specific lipid nanoparticle (LNP) delivery solutions. Under his leadership, Mana.bio has pioneered a data-driven approach to unlocking extrahepatic delivery of nucleic acid therapeutics. Prior to founding Mana.bio, Yogev co-founded Genome Compiler, a leading gene editing software platform that was acquired by Twist Bioscience (Nasdaq: TWST), a global leader in synthetic biology. Following the acquisition, he served as General Manager of Twist’s Israel R&D center, playing a key role in the company's IPO. Yogev later held a senior leadership position at monday.com (Nasdaq: MNDY), contributing to its successful IPO and growth as a global enterprise software leader.